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Background
Recent studies have shown an increase in the incidence
of coronary heart disease in HIV-infected patients on
treatment with abacavir (ABC), and platelet hyper-reac-
tivity induced by this drug has been suggested as a pos-
sible cause.
Objective
To assess platelet activity in HIV-infected patients with
and without antiretroviral therapy (ART), analysing the
influence of the presence or absence of ABC in the ART
regimen.
Patients and methods
Observational, cross-sectional, pilot study. Among
HIV-infected patients on regular follow-up in our Cen-
tre, we selected 30 asymptomatic patients: 20 on ART
for at least 24 weeks and with undetectable HIV viral
load, 10 on ABC, and 10 on tenofovir (TDF), and 10
naïve patients, in addition to a control group of 10
HIV-negative subjects from the same hospital area. No
subject was receiving drugs with antiagregant activity.
Platelet activity was assessed by measuring time-depen-
dent platelet aggregometry (electrical impedance on
fasting whole blood), induced by ADP (1,25 y 2,5 µM),
collagen (0.5 y 1 µg/mL), arachidonic acid (100 y 200
µM), and U46619 (receptor agonist of the tromboxano
A2) (1.25 y 2.5 µM). A bivariate analysis by t student,
anova and chi-square, and multivariate by linear
regression were performed. Statistic program: SPSS,
16.0.
Results
Demographic and anthropometric data, prevalence of
cardiovascular risk factors, lipid profile and fasting
glycemia were similar in all groups, but older age and
longer time of HIV infection in the ABC group (50.4 vs
36.1, 34.2 and 42.7 years, respectively; p<0.05, and 140.3
vs 88.1 and 48.3 months in the two other groups of HIV
patients; p< 0.05). Mean CD4 cells count in HIV-
patients was 564/mm
3. Platelet aggregation with expo-
sure to U46619 was higher in the ABC group compared
with the TDF group (11.1 vs 4.4%; p=0.007), naïve
patients (11.1 vs 5.7%; p=0.014), and the HIV-negative
group (11.1 vs 6.5%; p=0.04). These differences
remained significant when controlled for age and time
of HIV infection.
Conclusions
ABC increases platelet aggregability possibly in relation
with the receptor of tromboxano. Wider studies are
needed to confirm this hypothesis.
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